Granulocyte colony-stimulating factor effects on neurological and motor function in animals with spinal cord injury: a systematic review and meta-analysis

Spinal cord injury (SCI) is a serious neurological condition with limited effective treatments. Granulocyte colony-stimulating factor (G-CSF), typically used for other medical conditions, has shown potential in protecting nerve cells. This study investigates G-CSF's impact on motor and neurological functions in animal models with SCI, focusing on outcomes like BBB scale scores and electrophysiological results. The meta-analysis suggests G-CSF therapy may improve motor activity and provide neuroprotection in animal SCI models, offering preclinical evidence for potential human clinical trials.

• 1
  G-CSF intervention improves BBB scale scores in animal models of SCI at various time points (3, 7, 14, 28, and 35 days).
• 2
  G-CSF therapy significantly reduced the number of TUNEL-positive cells, indicating a reduction in apoptosis in SCI animal models.
• 3
  Network meta-analysis suggests that a dosage of 15 mg/kg-20 mg/kg of G-CSF may be an optimal dose for long-term efficacy in SCI animal models.